RxDoctor Payments Data

Jason Talbert, MD

Family Medicine · Madison Heights, MINPI 1972614659

Payments from drug & device makers

$3,885in general payments, 2019–2025

Across 222 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$595
  • Pfizer$455
  • GSK$369
  • AstraZeneca$344
  • AbbVie$326
  • Lilly USA, LLC$277
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$3,885100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,885 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$232,059
Medicare patients
526
Services billed
10,044

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide161$185,052
EliquisApixaban83$107,989
JardianceEmpagliflozin61$83,476
FarxigaDapagliflozin Propanediol25$37,231
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$35,262
XareltoRivaroxaban22$33,239
JanuviaSitagliptin Phosphate29$26,072
CreonLipase/Protease/Amylase15$15,154
MounjaroTirzepatide14$14,563
Breo ElliptaFluticasone/Vilanterol17$14,473
MyrbetriqMirabegron15$10,408
LinzessLinaclotide12$9,933
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen245$6,987
Atorvastatin Calcium494$5,897
Albuterol Sulfate HfaAlbuterol Sulfate121$5,044

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$595$185,052161 claims
PfizerEliquis, Prempro$455$111,68695 claims
Boehringer IngelheimJardiance$228$83,47661 claims
GSKTrelegy Ellipta, Breo Ellipta$369$49,73557 claims
AstraZenecaFarxiga$344$37,23125 claims
Johnson & JohnsonXarelto$15$33,23922 claims
AbbVieCreon, Linzess, Synthroid$326$28,74970 claims
MerckJanuvia$58$26,07229 claims
Lilly USA, LLCMounjaro$277$14,56314 claims
Astellas Pharma US IncMyrbetriq$62$10,40815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Madison Heights

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →